MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Merck & Co., Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$143.63−2.32 (-1.59%)
Close on Oct 19, 2026
- Market cap
- $354.77B
- P/E (TTM)
- 114.9
- Dividend yield
- 2.28%
Merck & Co., Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical | $59.56B | $58.85B | $58.14B | $57.34B | $56.67B | $57.03B | $57.40B | $56.50B | $55.82B | $54.87B | $53.58B | $52.62B | 89.5% | +5.1% |
| Animal Health | $6.69B | $6.56B | $6.35B | $6.25B | $6.12B | $5.95B | $5.88B | $5.76B | $5.67B | $5.65B | $5.63B | $5.58B | 10.0% | +9.3% |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $37.68B | $37.15B | $36.51B | $35.56B | $34.28B | $33.32B | $32.28B | $31.18B | $30.16B | $29.30B | $28.48B | $27.67B | 56.6% | +9.9% |
| Non-US | $28.75B | $28.45B | $28.13B | $28.16B | $28.65B | $29.82B | $31.13B | $31.19B | $31.53B | $31.36B | $30.87B | – | 43.2% | +0.3% |
| Europe, Middle East and Africa | $15.28B | $15.02B | $14.58B | $14.17B | $14.08B | $13.93B | $14.04B | $13.94B | $13.68B | $13.51B | $13.25B | $13.24B | 22.9% | +8.5% |
| Latin America | $3.51B | $3.49B | $3.41B | $3.42B | $3.46B | $3.45B | $3.46B | $3.38B | $3.34B | $3.22B | $3.09B | $2.95B | 5.3% | +1.5% |
| Asia Pacific (other than China and Japan) | $3.07B | $3.03B | $2.98B | $3.00B | $3.06B | $3.02B | $3.06B | $3.05B | $3.00B | $3.10B | $3.23B | $3.30B | 4.6% | +0.2% |
| Other | $2.90B | $2.85B | $2.88B | $2.80B | $2.62B | $2.64B | $2.56B | $2.46B | $2.30B | $2.18B | $2.10B | $2.23B | 4.4% | +10.6% |
| Japan | $2.55B | $2.60B | $2.71B | $2.84B | $3.07B | $3.13B | $3.28B | $3.10B | $3.24B | $3.23B | $3.16B | $3.37B | 3.8% | -16.9% |
| China | $1.59B | $1.63B | $1.94B | $2.44B | $3.05B | $4.42B | $5.49B | $6.09B | $6.76B | $6.86B | $6.80B | $6.56B | 2.4% | -48.0% |
| Intl | – | – | – | – | – | – | – | – | – | $32.11B | $31.64B | $31.64B | – | – |
From the segment and revenue-disaggregation notes of Merck's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.